AHA 2020 - Device Treatment Options for Heart Failure: Appropriate Patient Selection & Identification

November 20, 2020

In this video, Dr. Singh discusses device treatment options available to heart failure patients that remain sympotomatic despite being on guideline directed medical therapy.  CCM® therapy is discussed and the indications for use are outlined including:   NYHA Class III,  EF 25 - 45%, that remain symptomatic despite being treated with Guideline Directed Medical Therapy and that are NOT indicated for Cardiac Resynchronization Therapy.

  • October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Login to view comments. Click here to Login